Pharmacoenhancement of Protease Inhibitors
| Autor: | Walid Khayr, Bharat Motwani |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
medicine.medical_treatment
HIV Infections Pharmacology Drug Administration Schedule Pharmacotherapy Pharmacokinetics Drug Resistance Viral medicine Animals Cytochrome P-450 CYP3A Cytochrome P-450 Enzyme Inhibitors Humans HIV Protease Inhibitor Pharmacology (medical) Protease inhibitor (pharmacology) ATP Binding Cassette Transporter Subfamily B Member 1 Ritonavir Protease business.industry HIV Drug Synergism HIV Protease Inhibitors General Medicine Toxicity Drug Therapy Combination business medicine.drug |
| Zdroj: | American Journal of Therapeutics. 13:57-63 |
| ISSN: | 1075-2765 |
| DOI: | 10.1097/00045391-200601000-00010 |
| Popis: | Toxicity, adherence problems, and virological failure may limit treatment by protease inhibitor-containing regimens at standard doses. Addition of low-dose ritonavir results in a high plasma concentration of coadministered protease inhibitor resulting in decreased pill burden, a reduction in the number of doses, fewer food and/or fluid restrictions, and a higher rate of virological suppression. These effects are due to improved pharmacokinetics of coadministered protease inhibitors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|